POLYETHYLENE GLYCOL 3350 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Polyethylene Glycol 3350, and when can generic versions of Polyethylene Glycol 3350 launch?
Polyethylene Glycol 3350 is a drug marketed by Ani Pharms, Annora Pharma, Aurobindo Pharma Ltd, Breckenridge Pharm, Elysium, Lgm Pharma, Mylan, Nexgen Pharma Inc, Novel Labs Inc, Nuvo Pharms Inc, Paddock Llc, Perrigo R And D, Strides Pharma, and Teva Pharms. and is included in eighteen NDAs.
The generic ingredient in POLYETHYLENE GLYCOL 3350 is polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous. There are four hundred and twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous profile page.
Summary for POLYETHYLENE GLYCOL 3350
US Patents: | 0 |
Applicants: | 14 |
NDAs: | 18 |
Finished Product Suppliers / Packagers: | 59 |
Raw Ingredient (Bulk) Api Vendors: | 218 |
Clinical Trials: | 302 |
Formulation / Manufacturing: | see details |
DailyMed Link: | POLYETHYLENE GLYCOL 3350 at DailyMed |
Recent Clinical Trials for POLYETHYLENE GLYCOL 3350
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Vanderbilt University Medical Center | Phase 2/Phase 3 |
Chad R. Tracy | Phase 4 |
Hospital de Clínicas Dr. Manuel Quintela | N/A |
Pharmacology for POLYETHYLENE GLYCOL 3350
Drug Class | Osmotic Laxative |
Mechanism of Action | Osmotic Activity |
Physiological Effect | Stimulation Large Intestine Fluid/Electrolyte Secretion |